GlassScriptPhysician profile
Suneel M Koul
NPI 1881601276
$6,151.69
in general payments reported to CMS, 2019-2025
25 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 96% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $386 · 2021: $949 · 2022: $670 · 2023: $613 · 2024: $1,101 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,027.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,371.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $803.39 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $688.52 | 2019-2024 | Spravato |
| Novo Nordisk INC | $635.32 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $626.99 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $600.13 | 2023-2025 | |
| Glaxosmithkline, LLC. | $300.97 | 2019-2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $139.26 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $138.80 | 2022-2025 | |
| Braeburn INC. | $106.35 | 2024-2025 | Brixadi |
| Avanir Pharmaceuticals, INC. | $105.90 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $99.17 | 2021 | |
| Phathom Pharmaceuticals, INC. | $86.52 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $68.03 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $63.37 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $60.72 | 2019-2022 | |
| Alkermes, INC. | $47.27 | 2019-2021 | |
| Bardy Diagnostics, INC. | $40.45 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $37.82 | 2022-2023 | Prehevbrio |
| Sanofi Pasteur INC. | $30.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.76 | 2021 | |
| Amgen INC. | $23.03 | 2024 | Otezla, Repatha |
| Almatica Pharma LLC | $21.39 | 2022 | |
| Ascensia Diabetes Care US INC. | $19.90 | 2020 | |
| Indivior INC. | $13.47 | 2024 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suneel Koul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.